- 89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 months
- Results add to the overall survival (OS) benefit recently reported making CARVYKTI the first and only cell therapy to significantly extend OS versus standard therapies in multiple myeloma
- Landmark Phase 3 CARTITUDE-4 study data featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Reported Earlier, Legend Biotech CARVYKTI Delivers Improved MRD Negativity And Overall Survival Benefits In Phase 3 CARTITUDE-4 Study
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated